Evaluation of 3-Month Data for the Use of Erenumab for Chronic Migraine in Glasgow

    May 2022 in “ Journal of Neurology Neurosurgery & Psychiatry ”
    Krishna Dani, Lesley Murray, Anissa Benchiheub, George Gorrie, Johann Selvarajah, Sandeep Sharma, Michael McKenzie, Laura McCorkell, Christine Rankin, Alok Tyagi
    TLDR Erenumab significantly reduced migraine days or severity in most patients after 3 months.
    A 3-month audit of erenumab for chronic migraine prevention in Glasgow showed promising results. Data from 93 patients (86% female) revealed that 81% continued treatment due to significant reductions in headache days or severity. Previous treatments included various prophylactics, Botox, and neuromodulation. Side effects were reported in some patients, with constipation being the most common (23%). The study concluded that erenumab had a high response rate at 3 months, but 12-month data are needed to confirm the long-term efficacy.
    Discuss this study in the Community →